Year: 2021

Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trial All patients tolerated COMP360 psilocybin therapy wellLondon, UK – 13 December 2021           COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the results from its exploratory study of COMP360 psilocybin therapy in conjunction with SSRI use. This single-arm open label study of 19 patients taking concomitant SSRI therapy with COMP360 psilocybin therapy using a single dose of 25mg saw comparable treatment outcomes to patients in COMPASS’s phase IIb trial where patients were withdrawn from their SSRI prior to COMP360 psilocybin therapy. “The...

Award Was Presented in New York City at Plant Based World Expo 2021WPB AwardWinner World Plant Based AwardVANCOUVER, British Columbia, Dec. 13, 2021 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company, today announced that is has received the World Plant Based 2021 Award for its Plant-Based Complete Nutrition for Toddlers, as Best Dairy Product Alternative. The Award was announced this week at Plant Based World Expo in New York city. The World Plant-Based Awards, in association with Plant Based World Expo and FoodBev Media, are a celebration of innovation and excellence across the Plant-Based food and drink industry, honoring top innovative brands in the sector. Else was amongst dozens...

WINNEMUCCA, Nev., Dec. 13, 2021 (GLOBE NEWSWIRE) — Paramount Gold Nevada Corp. (“Paramount” or the “Company”) (NYSE American: PZG) announces the results of the votes from its annual general meeting of the stockholders which was held on December 9, 2021. There were 40,525,151 shares outstanding and entitled to vote at the meeting as of the record date of October 15, 2021, of which, 20,288,543 shares or 50.06% voted. The stockholders elected the following seven individuals to Paramount’s Board of Directors for a one year term expiring at the 2022 Annual General Meeting: Rudi Fronk, Glen Van Treek, Rachel Goldman, Christopher Reynolds, John Carden, Eliseo Gonzalez-Urien, and Pierre Pelletier. Detailed voting results of the election of directors were as follows:Name of Nominee   For Withheld PercentageFor PercentageWithheldRudi...

MONROE TOWNSHIP, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or “the Company”) (NYSE American: OPTT), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced Robert P. (Bob) Powers has been appointed by the Company’s Board of Directors as Senior Vice President and Chief Financial Officer, effective December 13, 2021. Mr. Powers brings more than 25 years of experience in finance and strategy to OPT, most recently as CFO of Constellation Advisors, a private equity-owned provider of outsourced back-office operations and compliance services. He has held financial leadership roles with Sterling Talent Solutions, Wood Group PPS – a division of Wood Group, GTE, SABIC Innovative Plastics, and Plug Power. He has also provided...

LA JOLLA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS). Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035. The allowed claims cover a method of treating a patient diagnosed with ALS with the combination of MN-166 (ibudilast) and riluzole. The allowed claims cover a wide range of dosage strengths of MN-166 (ibudilast) and riluzole and various formulations...

Embedded in Five9 Agent Desktop Plus, eGain Knowledge Hub for Five9 delivers proactive knowledge and AI conversational guidance to empower contact center agents SUNNYVALE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) — eGain Corporation (NASDAQ: EGAN), a leading cloud platform provider for customer engagement automation, today announced that its award-winning solution for knowledge management — eGain Knowledge Hub™ — has been accredited by Five9 and is now available on Five9 CX Marketplace. “The agent experience forms the foundation for delivering a great customer experience,” said Walt Rossi, Vice President of Business Development at Five9. “It’s important for contact centers to have the right tools in place to support their agents, especially as businesses have indicated that they will continue with a work-from-home or hybrid model....

NEXT GAMES CORPORATION COMPANY RELEASE 13 DECEMBER 2021 1:30 pm EET Next Games Corp.: Financial Reporting and Annual General Meeting in 2022 Next Games Corporation will publish its financial reports in 2022 as follows: • Financial Statement Bulletin for financial year 2021 on Friday 25 February, 2022 • Half-year report for January-June 2022 on Friday 19 August, 2022 Next Games’ Annual Report 2021 is scheduled to be published during the calendar week 11, 2022 at the latest. Next Games’ Annual General Meeting is planned to be held on Thursday 28 April, 2022. Next Games’ Investor calendar can be found on the company’s website at www.nextgames.com/investorsAdditional information: Saara BergströmChief Communications Officer+358 (0) 50 483 3896press@nextgames.comCertified Adviser: Alexander Corporate Finance Oy, puh. +358 (0) 50 520 4098 About...

Will expand patient access to breakthrough BPH treatment WAYNE, Pa., Dec. 13, 2021 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) today announced that the company has received reimbursement approval from the Central Social Insurance Medical Council of Japan (Chuikyo) of its UroLift System for patients who require treatment for benign prostatic hyperplasia (BPH). The UroLift System treatment is a minimally invasive approach to treating BPH, commonly known as an enlarged prostate, a condition that causes bothersome urinary symptoms in men. Performed as a same-day outpatient procedure,1 the UroLift System can help improve quality of life,2 and offers lasting relief from symptoms with minimal downtime for patients.1,3 Liam Kelly, Chairman, President and Chief Executive Officer said, “I am proud of how the team has achieved reimbursement...